• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Management of venous thromboembolism in patients with cancer: role of dalteparin.癌症患者静脉血栓栓塞的管理：达肝素的作用
Vasc Health Risk Manag. 2008;4(2):279-87. doi: 10.2147/vhrm.s2132.
2
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.阿哌沙班和达肝素治疗活动性恶性肿瘤相关静脉血栓栓塞症。ADAM VTE 试验。
Thromb Haemost. 2017 Oct 5;117(10):1952-1961. doi: 10.1160/TH17-03-0193. Epub 2017 Aug 24.
3
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.依度沙班治疗癌症相关静脉血栓栓塞症。
N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.
4
Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.癌症患者接受阿哌沙班或达肝素治疗后复发性静脉血栓栓塞和出血的早期时间进程。
Thromb Haemost. 2024 Jul;124(7):676-683. doi: 10.1055/s-0043-1778642. Epub 2024 Jan 9.
5
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.达肝素对静脉血栓栓塞高危癌症患者的血栓预防作用：一项随机试验。
Thromb Res. 2017 Mar;151:89-95. doi: 10.1016/j.thromres.2017.01.009. Epub 2017 Jan 26.
6
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.达肝素或维生素K拮抗剂预防癌症患者复发性静脉血栓栓塞：法国和奥地利的患者层面经济分析
Support Care Cancer. 2017 Jul;25(7):2093-2102. doi: 10.1007/s00520-017-3610-2. Epub 2017 Feb 15.
7
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.达肝素治疗癌症患者静脉血栓栓塞症长达 12 个月：DALTECAN 研究。
J Thromb Haemost. 2015 Jun;13(6):1028-35. doi: 10.1111/jth.12923. Epub 2015 May 10.
8
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.癌症相关静脉血栓栓塞症出血的临床影响：来自 Hokusai VTE 癌症研究的结果。
Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30.
9
Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Clin Appl Thromb Hemost. 2016 Oct;22(7):617-26. doi: 10.1177/1076029616658118. Epub 2016 Jul 19.
10
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.达肝素与未分级肝素预防危重症患者静脉血栓栓塞的成本效益比较。
JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

引用本文的文献

1
The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.注射剂在癌症相关血栓形成的治疗和预防中的作用。
Cancers (Basel). 2023 Sep 20;15(18):4640. doi: 10.3390/cancers15184640.
2
Anticoagulation prescribing patterns in patients with cancer.癌症患者的抗凝药物处方模式。
J Thromb Thrombolysis. 2018 Jan;45(1):89-98. doi: 10.1007/s11239-017-1558-1.
3
Pathophysiology and management of thrombosis in cancer: 150 years of progress.癌症相关血栓形成的病理生理学和管理：150 年的进展。
J Thromb Thrombolysis. 2013 Apr;35(3):346-51. doi: 10.1007/s11239-013-0897-9.

本文引用的文献

1
The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.长期使用低分子量肝素治疗晚期癌症姑息治疗患者的静脉血栓栓塞：62例病例系列
Palliat Med. 2007 Sep;21(6):473-6. doi: 10.1177/0269216307080816.
2
High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients.非小细胞肺癌患者深静脉血栓形成的高风险：一项对493例患者的队列研究。
J Thorac Oncol. 2007 Aug;2(8):729-34. doi: 10.1097/JTO.0b013e31811ea275.
3
Cancer and thrombosis: from molecular mechanisms to clinical presentations.癌症与血栓形成：从分子机制到临床表现
J Thromb Haemost. 2007 Jul;5 Suppl 1:246-54. doi: 10.1111/j.1538-7836.2007.02497.x.
4
Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT.肿瘤分期CT检查中发现的无症状静脉血栓栓塞性疾病的患病率及意义
AJR Am J Roentgenol. 2007 Jul;189(1):162-70. doi: 10.2214/AJR.07.2067.
5
Thalidomide and thrombosis. A meta-analysis.沙利度胺与血栓形成。一项荟萃分析。
Thromb Haemost. 2007 Jun;97(6):1031-6.
6
Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis.癌症手术患者发生静脉血栓栓塞的风险及血栓预防措施
J Surg Oncol. 2007 Feb 1;95(2):167-74. doi: 10.1002/jso.20625.
7
Risk of thrombosis with lenalidomide and its prevention with aspirin.来那度胺引发血栓形成的风险及其阿司匹林预防措施
Chest. 2007 Jan;131(1):275-7. doi: 10.1378/chest.06-2360.
8
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.长期使用低分子量肝素与常规治疗对癌症相关性近端静脉血栓形成患者的疗效比较
Am J Med. 2006 Dec;119(12):1062-72. doi: 10.1016/j.amjmed.2006.02.022.
9
Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans.癌基因、特鲁索综合征以及小鼠和人类凝血组中的癌症相关变化。
Cancer Res. 2006 Nov 15;66(22):10643-6. doi: 10.1158/0008-5472.CAN-06-2350.
10
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.活动性癌症患者静脉血栓栓塞事件的二级预防：单用依诺肝素与初始依诺肝素随后使用华法林治疗180天的比较。
Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96. doi: 10.1177/1076029606293692.

癌症患者静脉血栓栓塞的管理：达肝素的作用

Management of venous thromboembolism in patients with cancer: role of dalteparin.

作者信息

Linkins Lori-Ann

机构信息

Department of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, Canada.

出版信息

Vasc Health Risk Manag. 2008;4(2):279-87. doi: 10.2147/vhrm.s2132.

DOI:10.2147/vhrm.s2132
PMID:18561503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2496976/
Abstract

Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.

摘要

癌症是静脉血栓栓塞症（VTE）发生的主要风险因素。对于癌症患者，使用维生素K拮抗剂进行传统抗凝治疗存在更多问题，因为复发性VTE风险增加，且抗凝相关出血风险也增加。近年来，在治疗患有VTE的癌症患者时，已转向使用延长疗程的达肝素。达肝素是一种低分子肝素，已证明在患有VTE的癌症患者中比传统抗凝治疗更有效且同样安全。本文将（a）综述癌症与VTE之间的关系，以及（b）概述达肝素在癌症患者VTE管理中的作用。